GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
View Patent ↗In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).
1. A method of delaying the onset of type I diabetes, and/or slowing the progression of type I diabetes, and/or reducing the severity of type I diabetes in a mammal, said method comprising:
coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising preproinsulin or an immunogenic fragment thereof;
wherein said first compound and said second compound act synergistically and are administered in an amount sufficient to delay the onset of type I diabetes, and/or slow the progression of type I diabetes, and/or reduce the severity of type I diabetes in said mammal.
2. The method of claim 1 , wherein said first compound comprises GABA and said second compound comprises preproinsulin.
3. The method of claim 1 , wherein said first compound comprises GABA and said second compound comprises proinsulin or an immunogenic fragment thereof.
4. The method of claim 1 , wherein said first compound comprises GABA and said second compound comprises proinsulin.
5. A method of delaying the onset of hyperglycemia, and/or slowing the progression of hyperglycemia, and/or reducing the severity of hyperglycemia, said method comprising:
coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising preproinsulin or an immunogenic fragment thereof;
wherein said first compound and said second compound are administered in an amount sufficient to delay the onset of hyperglycemia, and/or slow the progression of hyperglycemia, and/or reduce the severity of hyperglycemia in said mammal.
6. The method of claim 5 , wherein said first compound and said second compound act synergistically.
7. The method of claim 5 , wherein said first compound comprises GABA and said second compound comprises preproinsulin.
8. The method of claim 5 , wherein said first compound comprises GABA and said second compound comprises proinsulin or an immunogenic fragment thereof.
9. The method of claim 5 , wherein said first compound comprises GABA and said second compound comprises proinsulin.
10. A method of promoting transplanted islet cell survival in a mammal having Type I diabetes or at risk for type I diabetes who is a recipient of transplanted islet cells, said method comprising:
coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising preproinsulin or an immunogenic fragment thereof;
wherein said first compound and said second compound are administered in an amount sufficient to promote transplanted islet cell survival in said mammal.
11. The method of claim 10 , wherein said first compound and said second compound act synergistically.
12. The method of claim 10 , wherein said first compound comprises GABA and said second compound comprises preproinsulin.
13. The method of claim 10 , wherein said first compound comprises GABA and said second compound comprises proinsulin or an immunogenic fragment thereof.
14. The method of claim 10 , wherein said first compound comprises GABA and said second compound comprises proinsulin.
15. A method of delaying the onset of an immune response, and/or slowing the progression of an immune response, and/or reducing the severity of an immune response, and/or suppressing an immune response in a mammal, said method comprising:
coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA);
a second compound comprising preproinsulin or an immunogenic fragment thereof;
wherein said first compound and said second compound act synergistically and are administered in an amount sufficient to delay the onset of an immune response, and/or slow the progression of an immune response, and/or reduce the severity of an immune response, and/or suppress an immune response in said mammal.
16. The method of claim 15 , wherein said first compound comprises GABA and said second compound comprises preproinsulin.
17. The method of claim 15 , wherein said first compound comprises GABA and said second compound comprises proinsulin or an immunogenic fragment thereof.
18. The method of claim 15 , wherein said first compound comprises GABA and said second compound comprises proinsulin.
19. A method of protecting beta-cells in a mammal from oxidative stress induced apoptosis said method comprising:
coadministering to a mammal containing said β-cells:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising preproinsulin or an immunogenic fragment thereof;
wherein said first compound and said second compound are administered in an amount sufficient to partially or fully protect said beta cells from oxidative stress induced apoptosis.
20. The method of claim 19 , wherein said first compound and said second compound act synergistically.
21. The method of claim 19 , wherein said first compound comprises GABA and said second compound comprises preproinsulin.
22. The method of claim 19 , wherein said first compound comprises GABA and said second compound comprises proinsulin or an immunogenic fragment thereof.
23. The method of claim 19 , wherein said first compound comprises GABA and said second compound comprises proinsulin.